A double-blind trial with baclofen (Lioresal) and diazepam in spasticity due to multiple sclerosis
- PMID: 1090103
- DOI: 10.1111/j.1600-0404.1975.tb01366.x
A double-blind trial with baclofen (Lioresal) and diazepam in spasticity due to multiple sclerosis
Abstract
In 17 in-patients suffering from spasticity due to multiple sclerosis, the effect and tolerability periods were 4 weeks each. As to efficacy, the variables: spasticity, clonus, flexor spasms, gait and bladder function were evaluated clinically. No significant difference was found between the two drugs. As far as side-effects are concerned, sedation was specifically inquired about. Apart from that, spontaneoulsy reported side-effects were recorded. Sedation was more often seen during treatment with diazepam, while the side-effects during baclofen treatment were more varied. The total number and severity of side-effects were equal in the two treatment groups. A preference for one of the two treatment periods was stated by the investigator before the code was broken. A significant difference (p less than 0.001) in favor of Lioresal was found. This is discussed in the light of the fact that no significant difference was found for the individual symptoms or side-effects.
Similar articles
-
A comparison of baclofen and diazepam in the treatment of spasticity.J Neurol Sci. 1974 Sep;23(1):17-24. doi: 10.1016/0022-510x(74)90137-3. J Neurol Sci. 1974. PMID: 4850175 No abstract available.
-
Evaluation of baclofen (Lioresal) for spasticity in multiple sclerosis.Postgrad Med J. 1975 Sep;51(599):615-8. doi: 10.1136/pgmj.51.599.615. Postgrad Med J. 1975. PMID: 1105499 Free PMC article. Clinical Trial.
-
Clonazepam, baclofen and placebo in the treatment of spasticity.Eur Neurol. 1977;16(1-6):257-62. doi: 10.1159/000114906. Eur Neurol. 1977. PMID: 354938 Clinical Trial.
-
Baclofen: a preliminary report of its pharmacological properties and therapeutic efficacy in spasticity.Drugs. 1974;8(1):1-14. doi: 10.2165/00003495-197408010-00001. Drugs. 1974. PMID: 4154834 Review. No abstract available.
-
Drug treatment of spasticity and rigidity.Mod Trends Neurol. 1975;6:205-21. Mod Trends Neurol. 1975. PMID: 1105140 Review. No abstract available.
Cited by
-
Using conditioned place preference to identify relapse prevention medications.Neurosci Biobehav Rev. 2013 Nov;37(9 Pt A):2081-6. doi: 10.1016/j.neubiorev.2013.05.002. Epub 2013 May 13. Neurosci Biobehav Rev. 2013. PMID: 23680702 Free PMC article. Review.
-
Role of cannabinoids in multiple sclerosis.CNS Drugs. 2011 Mar;25(3):187-201. doi: 10.2165/11539000-000000000-00000. CNS Drugs. 2011. PMID: 21323391 Review.
-
The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study.Drug Alcohol Depend. 2009 Jul 1;103(1-2):30-6. doi: 10.1016/j.drugalcdep.2009.02.014. Epub 2009 Apr 23. Drug Alcohol Depend. 2009. PMID: 19398283 Free PMC article. Clinical Trial.
-
A benefit-risk assessment of baclofen in severe spinal spasticity.Drug Saf. 2004;27(11):799-818. doi: 10.2165/00002018-200427110-00004. Drug Saf. 2004. PMID: 15350152 Review.
-
Comparison of dantrolene sodium and diazepam in the treatment of spasticity.J Neurol Neurosurg Psychiatry. 1976 Apr;39(4):350-6. doi: 10.1136/jnnp.39.4.350. J Neurol Neurosurg Psychiatry. 1976. PMID: 778344 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials